ADD/ADHD

Top Story

FDA approves Mydayis for ADHD in adolescents

June 21, 2017

The FDA recently approved Mydayis, a once-daily mixed salts of a single-entity amphetamine product from Shire, for treatment of ADHD in individuals aged 13 years and older.

"The approval of Mydayis provides clinicians with another option to treat their patients with ADHD ages 13 and older," study researcher Andrew J. Cutler, MD, executive vice president and chief medical officer at Meridien, told Healio/Psychiatry. "In particular, there is a need for more approved medications for adults with ADHD.  Adults have long days, which require control of symptoms in several settings, such as home, school or work, and socially.  In clinical trials in adults with ADHD, Mydayis was shown to treat symptoms of ADHD for up to 16 hours.  Mydayis therefore provides clinicians with a new once a day treatment that can be effective for their appropriate patients with ADHD ages 13 and older."

In the Journals

Comorbid ADHD, conduct disorder explains link between autism, violence

June 21, 2017
Autism was associated with an increased risk for violent crime; however, the association was significantly attenuated by comorbid ADHD or conduct disorder, according to…
FDA News

FDA approves disintegrating Cotempla tablet for ADHD

June 20, 2017
Neos Therapeutics Inc. recently announced the FDA approved Cotempla XR-ODT, an extended-release orally disintegrating tablet, for the treatment of ADHD in children aged…
In the Journals

Link between prenatal antidepressant use, ADHD risk may be overestimated

June 14, 2017
Prenatal antidepressant use and risk for ADHD may be partially due to confounding by indication of antidepressants, according to recent findings. “Recent studies…
CME Article

Managing Adult Attention-Deficit/Hyperactivity Disorder: To Treat or Not To Treat?

Psychiatric Annals, June 2017, Volume 47 Issue 6
Attention-deficit/hyperactivity disorder (ADHD) is a highly prevalent and chronic neurodevelopmental disorder often…
More »
CME

Child and Adolescent Psychiatry: January 2016

Keck School of Medicine of USC and Psychiatric Annals

“A person’s a person, no matter how small,” wrote Dr. Seuss in Horton Hears a Who!
In the mystery of…
More »
Featured
American Psychiatric Association Annual Meeting

American Psychiatric Association Annual Meeting

Video
Meeting News

VIDEO: New research shows additional symptom burden in adult ADHD

May 25, 2017
More »
FDA News

FDA approves Mydayis for ADHD in adolescents

June 21, 2017
The FDA recently approved Mydayis, a once-daily mixed salts of a single-entity amphetamine product from Shire, for treatment of ADHD in individuals…

In the Journals

Comorbid ADHD, conduct disorder explains link between autism, violence

June 21, 2017
Autism was associated with an increased risk for violent crime; however, the association was significantly attenuated by comorbid ADHD or conduct…

FDA News

FDA approves disintegrating Cotempla tablet for ADHD

June 20, 2017
Neos Therapeutics Inc. recently announced the FDA approved Cotempla XR-ODT, an extended-release orally disintegrating tablet, for the treatment of…

In the Journals

Link between prenatal antidepressant use, ADHD risk may be overestimated

June 14, 2017
Prenatal antidepressant use and risk for ADHD may be partially due to confounding by indication of antidepressants, according to recent findings…

In the Journals

Minority children on Medicaid less likely to continue ADHD treatment

June 8, 2017
Black and Hispanic children enrolled in Medicaid are significantly more likely to discontinue pharmacological treatment for…

Guest Editorial

Adult Attention-Deficit/Hyperactivity Disorder: A Diagnostics Challenge and Treatment Dilemma

Psychiatric Annals, June 2017, Volume 47 Issue 6
Adult attention-deficit/hyperactivity disorder (ADHD) has always been a difficult-to-diagnose disorder for clinicians. This is mostly due to the lack…

Editorial

Zombie Ideas About Adult Attention-Deficit/Hyperactivity Disorder

Psychiatric Annals, June 2017, Volume 47 Issue 6
Adult attention-deficit/hyperactivity disorder (ADHD) presents a host of challenges for clinicians. Some don't believe it exists. Most don't…

CME Article

Managing Adult Attention-Deficit/Hyperactivity Disorder: To Treat or Not To Treat?

Psychiatric Annals, June 2017, Volume 47 Issue 6
Attention-deficit/hyperactivity disorder (ADHD) is a highly prevalent and chronic neurodevelopmental disorder often with residual symptoms throughout…

CME Article

Adult Attention-Deficit/Hyperactivity Disorder: Diagnostic Dilemma with Case Examples

Psychiatric Annals, June 2017, Volume 47 Issue 6
Attention-deficit/hyperactivity disorder (ADHD) usually is considered a childhood disease, and the Diagnostic and Statistical Manual of Mental…

CME Article

To Prescribe or Not? Pharmacological Options in Adult Attention-Deficit/Hyperactivity Disorder

Psychiatric Annals, June 2017, Volume 47 Issue 6
As children with attention-deficit/hyperactivity disorder (ADHD) age out of childhood and adolescence and into adulthood, their symptoms often…

More Headlines »
Advertisement
Advertisement